Cytokinetics Inc CYTK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $75.21
- Day Range
- $75.75–79.30
- 52-Week Range
- $31.99–80.20
- Bid/Ask
- $77.60 / $79.00
- Shares Outstanding
- 135.77M
- Market Cap
- $10.61B
- Volume/Avg
- 69 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 80.41
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 673
- Website
- https://www.cytokinetics.com
Competitors
Valuation
|
Metric
|
CYTK
|
SNY
|
BMY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 10.51 | 9.67 |
Price/Book Value | — | 1.27 | 5.81 |
Price/Sales | 80.41 | 1.96 | 2.40 |
Price/Cash Flow | — | 9.00 | 7.92 |
Price/Earnings
CYTK
SNY
BMY
Financial Strength
|
Metric
|
CYTK
|
SNY
|
BMY
|
|---|---|---|---|
Quick Ratio | 4.14 | 0.20 | 1.18 |
Current Ratio | 4.21 | 1.01 | 1.42 |
Interest Coverage | −6.66 | 11.82 | 6.31 |
Quick Ratio
CYTK
SNY
BMY
Profitability
|
Metric
|
CYTK
|
SNY
|
BMY
|
|---|---|---|---|
Return on Assets (Normalized) | −44.94% | 7.49% | 13.15% |
Return on Equity (Normalized) | — | 13.70% | 65.90% |
Return on Invested Capital (Normalized) | −94.89% | 10.47% | 19.89% |
Return on Assets
CYTK
SNY
BMY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Affymax Inc
AFFY
| — | Shdf | — | |||
| Athersys Inc
ATHXQ
| — | Bfs | — | |||
| Vertex Pharmaceuticals Inc
VRTX
| Nyprcsvrh | Sddqzbl | $116B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gznsdzzj | Cckxym | $64B | |||
| argenx SE
ARGNF
| — | Fps | $56B | |||
| argenx SE ADR
ARGX
| Dkkmckfb | Mslz | $56B | |||
| UCB SA
UCBJF
| — | Kmhj | $56B | |||
| UCB SA ADR
UCBJY
| — | Dcf | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Nbkjsdxd | Mjpmqw | $38B | |||
| CSL Ltd
CMXHF
| — | Whztp | $36B |
United States